New Horizon for Treatment of Inherited Retinal Dystrophy


Over the past twelve months there has been significant advancements in cell gene therapy for inherited retinal dystrophy, with an FDA approval of Spark Therapeutics’ Voretigene – the first gene therapy approved in ophthalmology. The company’s Clinical Ophthalmic Lead, Daniel Chung will be speaking at the 2nd annual Ophthalmic Drugs Conference in London on 26th November, where he will share his experiences on the development of Voretigene and its success. He will also discuss upcoming gene therapy trials and market access difficulties.

Daniel will be joined by a senior panel of big pharma and ophthalmic organisations to discuss the latest developments and innovations in ocular gene editing including:

Alan Stitt, Dean of Innovation and Impact, Queen’s University Belfast
Mitchell de long
, Vice President, Chemistry, Aerie Pharmaceuticals
Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen
Majid Anderesi
, Associate Group Clinical Director, Ophthalmology, Roche
Caroline Barelle
, CEO, Elasmoge
Victor Chong
, Global Head of Ophthalmology, Boehringer Ingelheim
Aniz Girach
, Chief Medical Officer, Nightstar Therapeutics
Peter Morgan-Warren
, Medical Assessor, Licensing Division, MHRA
David Silverman
, Clinical Director, Ophthalmology, Roche

Programme highlights include recent advances in the treatment of glaucoma; recent applications of artificial intelligence in drug discovery and biomarkers and surrogate end-points from a regulatory perspective.


Sponsors: Aero Pump | Experimentica | Nemera


Contact Information:

For all media inquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 / Email:

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

profile mask

Pav Solanki